ENLV Enlivex Therapeutics Ltd.

8.03
-0.08  -1%
Previous Close 8.11
Open 7.98
Price To Book 5.28
Market Cap 81,213,067
Shares 10,113,707
Volume 45,810
Short Ratio
Av. Daily Volume 44,238
Stock charts supplied by TradingView

NewsSee all news

  1. Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies

    Nes-Ziona, Israel, Oct. 10, 2019 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced today that the European and Int'l Shock Societies  selected,

  2. European Patent Office Grants New Patent Covering Enlivex's Allocetra™ Immunotherapy Treatment

    Nes-Ziona, Israel, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the European Patent Office granted a new patent (#EP 2 929 015 B1) covering

  3. Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization's 2019 Cell Death in Immunity and Inflammation Workshop

    Nes-Ziona, Israel, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced that the European Molecular Biology Organization (EMBO) selected,

  4. First Data On Combination Of Enlivex's Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference

    Nes-Ziona, Israel, Sept. 23, 2019 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced the first presentation of its preclinical studies, which were

  5. New Patent Covering Enlivex's AllocetraTM Immunotherapy Was Allowed By The Israeli Patent Authority

    Nes-Ziona, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israeli Patent Authority issued a notice of allowance for a patent

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to be initiated 2Q 2021.
Allocetra
GvHD - steroid refractory
Phase 2 trial to be initiated 1Q 2020.
Allocetra
Prevention of cytokine storms in Sepsis
Phase 2/3 trial to be initiated 1Q 2020.
Allocetra
Prevention of GvHD & Transplant Complications

Latest News

  1. Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies

    Nes-Ziona, Israel, Oct. 10, 2019 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced today that the European and Int'l Shock Societies  selected,

  2. European Patent Office Grants New Patent Covering Enlivex's Allocetra™ Immunotherapy Treatment

    Nes-Ziona, Israel, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the European Patent Office granted a new patent (#EP 2 929 015 B1) covering

  3. Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization's 2019 Cell Death in Immunity and Inflammation Workshop

    Nes-Ziona, Israel, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced that the European Molecular Biology Organization (EMBO) selected,

  4. First Data On Combination Of Enlivex's Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference

    Nes-Ziona, Israel, Sept. 23, 2019 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced the first presentation of its preclinical studies, which were

  5. New Patent Covering Enlivex's AllocetraTM Immunotherapy Was Allowed By The Israeli Patent Authority

    Nes-Ziona, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israeli Patent Authority issued a notice of allowance for a patent